​

Atai Beckley Stock (NASDAQ:ATAI)

RevenueOwnershipFinancialsChart
Atai Beckley by TradingView

Previous Close

$4.13

52W Range

$1.15 - $6.75

50D Avg

$5.20

200D Avg

$3.09

Market Cap

$869.87M

Avg Vol (3M)

$6.08M

Beta

1.60

Div Yield

-

ATAI Company Profile

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

NL

Employees

54

IPO Date

Jun 18, 2021

Website

ATAI Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Research And Development Services$300.00K$300.00K$200.00K

Fiscal year ends in Dec 24 | Currency in USD

ATAI Financial Summary

Dec 24Dec 23Dec 22
Revenue-$314.00K$233.00K
Operating Income$-102.69M$-125.47M$-144.79M
Net Income$-149.27M$-40.22M$-141.41M
EBITDA$-102.69M$-36.31M$-135.01M
Basic EPS$-0.93$-0.25$-0.91
Diluted EPS$-0.93$-0.25$-0.91

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 22Nov 11, 22 | 8:30 AM
Q2 22Aug 15, 22 | 8:30 AM
Q1 22May 16, 22 | 8:30 AM

Peer Comparison

TickerCompany
IMTXImmatics N.V.
ELVNEnliven Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
RLAYRelay Therapeutics, Inc.
NKTRNektar Therapeutics
SANASana Biotechnology, Inc.
SNDXSyndax Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.
INBXInhibrx Biosciences, Inc.
DNTHDianthus Therapeutics, Inc.